Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs

Haemophilia

Volumn 17, Issue 5, 2011, Pages

  Karpf, D M ^a   Kjalke, M ^a   Thim, L ^a   Agerso H ^a   Merricks, E P ^b   Defriess, N ^b   Nichols, T C ^b   Ezban, M ^a  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Factor VIII; Haemophilia A; N8; Pharmacodynamics; Pharmacokinetics; Thromboelastography

Indexed keywords

BLOOD CLOTTING FACTOR 8C; N8; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CROSSOVER PROCEDURE; DOG; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; EX VIVO STUDY; FEMALE; HEMOPHILIA A; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; THROMBOELASTOGRAPHY;

ANIMALS; BLOOD COAGULATION; CROSS-OVER STUDIES; DOG DISEASES; DOGS; DRUG EVALUATION, PRECLINICAL; FACTOR VIII; FEMALE; HALF-LIFE; HEMOPHILIA A; HEMOSTASIS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; RECOMBINANT PROTEINS;

EID: 80052033319     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02580.x     Document Type: Article

References (20)

1. Castaldo G, D'Argenio V, Nardiello P et al. Haemophilia A: molecular insights. Clin Chem Lab Med 2007; 45: 450-61.
2. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 2003; 17(Suppl. 1): S1-5.
3. Keeney S, Mitchell M, Goodeve A. The molecular analysis of haemophilia A: a guideline from the UK haemophilia centre doctors' organization haemophilia genetics laboratory network. Haemophilia 2005; 11: 387-97.
4. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
5. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007; 370: 439-48.
6. Skinner MW. Treatment for all: a vision for the future. Haemophilia 2006; 12(Suppl. 3): 169-73.
7. Berntorp E. Progress in haemophilic care: ethical issues. Haemophilia 2002; 8: 435-8.
8. Thim L, Vandahl B, Karlsson J et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 2010; 16: 349-59.
9. Christiansen ML, Balling KW, Persson E et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia 2010; 16: 878-87.
10. ®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia 2011; doi.
11. Brinkhous KM, Sandberg H, Garris JB et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985; 82: 8752-6.
12. Brinkhous K, Sandberg H, Widlund L et al. Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. Semin Thromb Hemost 2002; 28: 269-72.
13. Nichols TC, Dillow AM, Franck HW et al. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR J 2009; 50: 144-67.
14. Cameron C, Notley C, Hoyle S et al. The canine factor VIII cDNA and 5' flanking sequence. Thromb Haemost 1998; 79: 317-22.
15. Advate Prescribing Information. Westlake Village, CA: Baxter Healthcare Corporation, March 2010. Available at Accessed February 14, 2011.
16. Sabatino DE, Lange AM, Altynova ES et al. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther 2011; 19: 442-9.
17. Kasper CK, Aledort L, Aronson D et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
18. Finn JD, Ozelo MC, Sabatino DE et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 2010; 116: 5842-8.
19. Kay MA, Rothenberg S, Landen CN et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 1993; 262: 117-9.
20. Nichols TC, Bellinger DA, Reddick RL et al. The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A. Blood 1993; 81: 2644-51.